Skip CCR Main Navigation National Cancer Institute National Cancer Institute U.S. National Institutes of Health
CCR - For Our Staff| Home |

Our Science – Jenkins Website

Lisa M. Jenkins, Ph.D.

Selected Publications

1)  Tanoue K, Miller Jenkins LM, Durell SR, Debnath S, Sakai H, Tagad HD, Ishida K, Appella E, Mazur SJ.
Binding of a Third Metal Ion by the Human Phosphatases PP2Ca and Wip1 Is Required for Phosphatase Activity.
Biochemistry. 52: 5830-43, 2013.
2)  Humbard MA, Surkov S, De Donatis GM, Jenkins L, Maurizi MR.
The N-degradome of escherichia coli: limited proteolysis in vivo generates a large pool of proteins bearing N-degrons.
J. Biol. Chem. 2013.
3)  Jenkins LM, Durell SR, Mazur SJ, Appella E.
p53 N-terminal phosphorylation: a defining layer of complex regulation.
Carcinogenesis. 33: 1441-9, 2012.
4)  Cheng-Mayer C, Huang Y, Gettie A, Tsai L, Ren W, Shakirzyanova M, Sina ST, Trunova N, Blanchard J, Jenkins LM, Lo Y, Schito ML, Appella E.
Delay of simian human immunodeficiency virus infection and control of viral replication in vaccinated macaques challenged in the presence of a topical microbicide.
AIDS. 25: 1833-41, 2011.
5)  Ohnuma S, Chufan E, Nandigama K, Jenkins LM, Durell SR, Appella E, Sauna ZE, Ambudkar SV.
Inhibition of multidrug resistance-linked P-glycoprotein (ABCB1) function by 5'-fluorosulfonylbenzoyl 5'-adenosine: evidence for an ATP analogue that interacts with both drug-substrate-and nucleotide-binding sites.
Biochemistry. 50: 3724-35, 2011.
6)  Hayashi R, Tanoue K, Durell SR, Chatterjee DK, Jenkins LM, Appella DH, Appella E.
Optimization of a cyclic peptide inhibitor of Ser/Thr phosphatase PPM1D (Wip1).
Biochemistry. 50: 4537-49, 2011.
7)  Zhou Z, Feng H, Zhou BR, Ghirlando R, Hu K, Zwolak A, Miller Jenkins LM, Xiao H, Tjandra N, Wu C, Bai Y.
Structural basis for recognition of centromere histone variant CenH3 by the chaperone Scm3.
Nature. 472: 234-7, 2011.
8)  Fujita K, Horikawa I, Mondal AM, Jenkins LM, Appella E, Vojtesek B, Bourdon JC, Lane DP, Harris CC.
Positive feedback between p53 and TRF2 during telomere-damage signalling and cellular senescence.
Nat. Cell Biol. 12: 1205-12, 2010.
9)  Miller Jenkins LM, Ott DE, Hayashi R, Coren LV, Wang D, Xu Q, Schito ML, Inman JK, Appella DH, Appella E.
Small-molecule inactivation of HIV-1 NCp7 by repetitive intracellular acyl transfer.
Nat. Chem. Biol. 6: 887-9, 2010.
10)  Iera JA, Jenkins LM, Kajiyama H, Kopp JB, Appella DH.
Solid-phase synthesis and screening of N-acylated polyamine (NAPA) combinatorial libraries for protein binding.
Bioorg. Med. Chem. Lett. 20: 6500-3, 2010.
11)  Goldschmidt V, Jenkins LM, de Rocquigny H, Darlix JL, Mely Y.
The nucleocapsid protein of HIV-1: a promising therapeutic target for antiviral drugs.
HIV Therapy. 4: 179-98, 2010.
12)  Hansen DF, Zhou Z, Feng H, Miller Jenkins LM, Bai Y, Kay LE.
Binding kinetics of histone chaperone Chz1 and variant histone H2A.Z-H2B by relaxation dispersion NMR spectroscopy.
J. Mol. Biol. 387: 1-9, 2009.
13)  Wallace GS, Cheng-Mayer C, Schito ML, Fletcher P, Miller Jenkins LM, Hayashi R, Neurath AR, Appella E, Shattock RJ.
Human immunodeficiency virus type 1 nucleocapsid inhibitors impede trans infection in cellular and explant models and protect nonhuman primates from infection.
J. Virol. 83: 9175-82, 2009.
14)  Feng H, Jenkins LM, Durell SR, Hayashi R, Mazur SJ, Cherry S, Tropea JE, Miller M, Wlodawer A, Appella E, Bai Y.
Structural basis for p300 Taz2-p53 TAD1 binding and modulation by phosphorylation.
Structure. 17: 202-10, 2009.
15)  Jenkins LM, Yamaguchi H, Hayashi R, Cherry S, Tropea JE, Miller M, Wlodawer A, Appella E, Mazur SJ.
Two distinct motifs within the p53 transactivation domain bind to the Taz2 domain of p300 and are differentially affected by phosphorylation.
Biochemistry. 48: 1244-55, 2009.
Click Here to View Collapsed Bibliography.

This page was last updated on 9/6/2013.